French molecular imaging firm Advanced Accelerator Applications (AAA) has garnered $28.7 million (23 million euros) in financing from U.S.-based investors.
The company plans to use the funds to prepare for phase III clinical trial results for its Lutathera radiopharmaceutical, and to continue development of its other nuclear medicine products.
Lutathera (Lu-177 DOTATATE) is a compound currently under development for the treatment of midgut neuroendocrine tumors.
